 | SCRAS IHB Research and Development Z.I. de Courtaboeuf 5, avenue du Canada 91966 Les Ulis Cedex France Tel.: +33 (0)1 60 92 20 00 Fax: +33 (0)1 69 07 38 02 Website: http://www.ipsen.com/ |
Ipsen is an innovation driven international specialty pharmaceutical group, which currently markets more than 20 drugs, employing nearly 4,000 people around the world.
Its development strategy is based on a complementary combination of specialised products, which are growth drivers, in the Group’s targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) and primary care products, which help finance its Research and development activities. The location of its four Research and Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active partnership policy.
Ipsen has industrial sites in France, the United Kingdom, Ireland, Switzerland, China and the United States, and plantations and leaf-drying facilities in France, China and the United States. Each of the Group’s manufacturing facilities focuses on a particular technology to maximise its operational efficiency. For instance, the Dublin site (Ireland) is devoted to the purification and formulation of proteins, while the Dreux plant (France) specialises in the manufacturing and packaging of high volumes of oral formulations.
Furthermore, Ipsen promotes continuous productivity improvement of its manufacturing processes. Upstream efforts by manufacturing, development and research teams promote mutual enhancement. This integration is a necessary step towards improving product quality, guaranteeing patient safety and developing optimal manufacturing processes within the Group’s cost optimisation rationale.
Products
In both its targeted therapeutic areas and in primary care, Ipsen has a diversified portfolio of leading medicines that have demonstrated a good safety profile.
The Group's product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), which are its primary areas of development. The Group also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular and cognitive disorders). To a great extent, these are composed of primary care.
Targeted therapeutic areas
Oncology: Decapeptyl®
Endocrinology: Somatuline®, NutropinAq®, Increlex®
Neuromuscular disorders: Dysport®
Primary care
Gastroenterology: Smecta®, Forlax®
Cognitive disorders: Tanakan®
Cardiovascular: Ginkor Fort®, Nisis® & Nisisco®
Contact information:
France — Manufacturing and Supply Organisation
SCA Saint Jean d'Illac
Chemin du Blayais
33127 Saint Jean d'Illac
France
Tel: +33 (0)5 56 21 67 75
Fax: +33 (0)5 56 21 87 00
France — Manufacturing and Supply Organisation
SCA Saint Jean d'Illac
Plantation Captieux - Les cultures
33840 Captieux
France
Tel: +33 (0)5 56 65 68 34
Fax: +33 (0)5 56 65 68 57
France — Manufacturing and Supply Organisation
Beaufour Ipsen Industries SAS
rue d'Ethe Virton
28100 Dreux
France
Tel: +33 (0)2 37 65 46 00
Fax: +33 (0)2 37 46 85 98
France — Manufacturing and Supply Organisation
Beaufour Ipsen Industries SAS
Saint Véran — Chemin de Reydet
84800 L'Isle-sur-la-Sorgue
France
Tel: +33 (0)4 90 21 27 00
Fax: +33 (0)4 90 38 20 65
France — Manufacturing and Supply Organisation
Ipsen Pharma Biotech SAS
Z.E. de Signes — CD 402
83870 Signes
France
Tel: +33 (0)4 94 10 76 76
Fax: +33 (0)4 94 10 76 79
France — International Operations
Beaufour Ipsen Pharma
37, rue Spontini
75116 Paris
France
Tel: +33 (0)1 53 65 76 00
Fax: +33 (0)1 47 55 84 44
France — France Operations
Beaufour Ipsen Pharma
24 rue Erlanger
75016 Paris
France
Tel: +33 (0)1 44 96 13 13
Fax: +33 (0)1 44 96 11 99
France — Ipsen Corporate Headquarters
Ipsen
42, rue du Dr Blanche
75016 Paris
France
Tel: +33 (0)1 44 30 43 43
Fax: +33 (0)1 44 30 43 21
France — Research and Development
SCRAS IHB
Z.I. de Courtaboeuf
5, avenue du Canada
91966 Les Ulis cedex
France
Tel: +33 (0)1 60 92 20 00
Fax: +33 (0)1 69 07 38 02
Source: Ipsen
History
The Ipsen story began when Laboratoires Beaufour was founded in 1929 by Dr. Henri Beaufour. In 1969 the Institut Henri Beaufour research centre was founded. In 1975, IPSEN was created (Institut de Produits de Synthese et d'Extraction Naturelle). Ipsen (Greece) was formed in 1980, and Ipsen International was created in 1981 in London to coordinate clinical and regulatory affairs, followed by Ipsen in Belgium in 1982. Fondation Ipsen was founded in France in 1983. In 1986, Laboratoires Astier was acquired and Ipsen Biotech was formed, and in 1987 the first Asian office was opened. 1986 saw the acquisition of LASA Laboratories in Spain (now called Ipsen Pharma), and expansion into the USA. In 1994, Speywood was acquired in the UK (now named Ipsen). In 2003, Beaufour Ipsen changed its name to Ipsen.
Ipsen's strategy relies on three factors: operational excellence in selected therapeutic areas, a policy of active alliances both in R&D and operations, and an effort to expand the international scope of the business. Ipsen carries out R&D, Formulation and Production, and Marketing. Ipsen is the fifth largest French pharmaceutical company. Ipsen operates from four R&D sites: Biotechnology in the USA (Boston), International Clinical Development, Business Development and Licensing in the UK (London), Formulation Research in Spain (Barcelona) and therapeutic agents of low molecular weight in France (Paris). The company's subsidiaries are located in Europe, the USA, and Asia/Australia. In the rest of the world, Ipsen operates through commercial partnerships.
Source: Pharmalicensing
